No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer
DOI:
https://doi.org/10.2340/sju.v61.46892Keywords:
Urinary bladder neoplasms, urethral neoplasm, endoscopy urethraAbstract
Objective: The Gold standard treatment for muscle-invasive bladder cancer (MIBC) in medically fit patients is neoadjuvant chemotherapy (NAC), followed by radical cystectomy (RC), usually urethra-sparing. Swedish guidelines recommend yearly urethroscopies for 5 years post-RC to detect urethral recurrences (URs). Evidence is limited regarding optimal urethral surveillance in the NAC-era for patients with MIBC. The goal was to evaluate UR-frequency across NAC-response groups: complete response (CR), i.e. pT0N0M0, and Non-CR-responses (partial response, stable disease, and progressive disease), compared with cystectomy-only controls.
Materials and methods: A multicenter retrospective cohort study including 241 patients with ≥T2 disease in clinical and/or pathological staging (post-RC), urothelial or mixed urothelial histology, and undergoing urethra-sparing cystectomy between 2010 and 2024. Data were retrieved from medical records and transferred into an ethically approved database. UR was biopsy-confirmed; time to UR was analyzed using Aalen–Johansen cumulative incidence functions with the Gray’s test.
Results: 40% (50/123) of the NAC-patients were complete responders. Nine UR-events occurred (3.7%) in the total material. UR was observed in 3/123 (2.4%) NAC-treated and 6/118 (5.1%) in No-NAC patients (Gray’s, p = 0.291). No UR occurred among complete responders to NAC (0/50) versus 3/73 in non-complete responders (Gray’s, p = 0.150). Four UR-cases (44.4%) were symptom-detected (urethral bleeding).
Conclusions: The total absence of urethral recurrences in NAC- and RC-treated MIBC-patients with complete responses suggests that the current Swedish recommendation of yearly urethroscopies could be reviewed since a more individualized surveillance strategy based on NAC-response may reduce unnecessary procedures.
Downloads
References
EAU guidelines on muscle-invasive and metastatic bladder cancer – Uroweb [Internet]. [cited 2026 May 5]. Available from: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/epidemiology-aetiology-and-pathology
Socialstyrelsen. Statistikdatabas [Internet]. 2025 [cited 2026 May 5]. Available from: https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/
Primär behandling [Internet]. [cited 2026 May 4]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/#chapter-11-1-1-Icke-muskelinvasiv-blascancer
Nationellt vårdprogram cancer i urinblåsa, njurbäcken, urinledare och urinrör [Internet]. [cited 2026 May 5]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/urinblase-och-urinvagscancer/vardprogram/
Primär behandling [Internet]. [cited 2026 May 5]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/
Rydell H, Ericson A, Eriksson V, et al. Thromboembolic events in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a study of renal impairment in relation to potential thromboprophylaxis. J Pers Med. 2022;12(12):1961.
Gopalakrishnan D, Elsayed AS, Hussein AA, et al. Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: results from the International Robotic Cystectomy Consortium. Int J Urol. 2022;29(3):197–205.
Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297–303.
Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238.
Fahmy O, Khairul-Asri MG, Schubert T, et al. Urethral recurrence after radical cystectomy for urothelial carcinoma: a systematic review and meta-analysis. Urol Oncol. 2018;36(2):54–59.
Boorjian SA, Kim SP, Weight CJ, et al. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol. 2011;60(6):1266–1272.
Li X, Wang W, Zhu G, et al. Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients. Oncotarget. 2018;9(2):2782–2796.
Boorjian SA, Tollefson MK, Cheville JC, et al. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol. 2011;186(5):1796–1802.
Giannarini G, Kessler TM, Thoeny HC, et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol. 2010;58(4):486–494.
Kusaka A, Hatakeyama S, Hosogoe S, et al. Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer. Med Oncol. 2017;34(5):90.
Nieuwenhuijzen JA, de Vries RR, van Tinteren H, et al. Follow-up after cystectomy: regularly scheduled, risk adjusted, or symptom guided? Patterns of recurrence, relapse presentation, and survival after cystectomy. Eur J Surg Oncol. 2014;40(12):1677–1685.
Alimi Q, Verhoest G, Kammerer-Jacquet SF, et al. Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer. Int J Urol. 2016;23(10):840–846.
Osterman CK, Alanzi J, Lewis JD, et al. Association between symptomatic versus asymptomatic recurrence and survival in bladder cancer. Clin Genitourin Cancer. 2018;16(3):235–239.
Uppföljning [Internet]. [cited 2026 May 5]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/
Laukhtina E, Moschini M, Soria F, et al. Follow-up of the urethra and management of urethral recurrence after radical cystectomy: a systematic review and proposal of management algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. Eur Urol Focus. 2022;8(6):1635–1642.
Zhou X, Ji H, Zhang H, et al. Treatment and outcomes of urethral recurrence after orthotopic neobladder replacement in patients with bladder cancer – practice in a single centre. J Int Med Res. 2018;46(9):3928–3937.
Milling RV, Nielsen NK, Graugaard-Jensen C, et al. Long-term effect of treatment for non-muscle invasive bladder cancer on quality of life: a cross-sectional study. Scand J Urol. 2025;60:141–147.
Torikka Suua S, Porserud A, Nygren-Bonnier M, et al. Association between physical function before radical cystectomy for urinary bladder cancer and recovery after discharge from hospital. Scand J Urol. 2025;60:135–140.
Sherwood JB, Sagalowsky AI. The diagnosis and treatment of urethral recurrence after radical cystectomy. Urol Oncol. 2006;24(4):356–361.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sofia Lingefelt, Viktor Nystrand, Farhood Alamdari, Johan Svensson, Amir Sherif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
